- Market Size Overview
- Market Dynamics
- Segmentation Insights
- Regional Insights
- Competitive Overview
- Recent Developments
- Scope of the Report
- List of Segments Covered
- FAQs

Global Tecovirimat Market Size, Share, Trends & Growth Analysis Report Segmented By Product Form (Transdermal Patch, Injectable, Oral, Topical Cream), Application, Age Group, Distribution Channel, End User And Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), 2026-2034
Tecovirimat Market Size Overview
The global tecovirimat market size was valued at USD 122.69 Million in 2025 and is projected to grow from USD 145.23 Million in 2026 to USD 559.74 Million by 2034, at a CAGR of 18.37% during the forecast period.
The tecovirimat market represents the global ecosystem surrounding the production, distribution, and clinical use of tecovirimat, an antiviral therapy developed primarily for orthopoxvirus infections such as smallpox and monkeypox. Tecovirimat functions by inhibiting viral envelope formation, thereby limiting viral spread within the host. The market gained strategic relevance following increased global preparedness initiatives after the 2001 bioterrorism concerns and subsequent public health stockpiling programs led by agencies such as the U.S. centres for disease control and prevention and the biomedical advanced research and development authority.
More recently, the 2022–2024 monkeypox outbreaks accelerated procurement activities across North America and Europe, expanding tecovirimat market demand within emergency response frameworks. Historically, the market was limited to government stockpiles under biosecurity programs; however, evolving outbreak patterns have gradually broadened its clinical relevance. The market includes product forms such as oral capsules, injectables, topical creams, and transdermal patches, distributed through hospital pharmacies, research institutes, and direct patient channels.
Expansion is supported by global immunization gaps, increased zoonotic spillover events reported by the world health organization, and enhanced surveillance systems. Two key highlights include growing government-funded antiviral stockpiles and regulatory fast-track approvals in multiple jurisdictions.
Tecovirimat Market Trends
The tecovirimat market is moving toward strategic stockpiling, diversified formulations, and broader clinical preparedness programs. End-user behavior is evolving from reactive outbreak response to proactive antiviral procurement planning. Following the world health organization’s declaration of monkeypox as a public health emergency of international concern in 2022, multiple governments increased antiviral reserves under national emergency frameworks. The U.S. government allocated hundreds of millions of dollars toward orthopoxvirus preparedness under Barda contracts, reinforcing tecovirimat market size expansion without reflecting commercial retail trends.
Digital pharmacovigilance systems and ai-driven outbreak modeling are influencing procurement cycles, enabling earlier antiviral deployment. Additionally, injectable and pediatric-friendly formulations are under evaluation to address vulnerable populations, including immunocompromised and geriatric groups. Regulatory agencies such as the U.S. FDA and the European medicines agency have supported expanded access protocols, improving clinical reach. The market is also seeing increased collaboration between biotechnology firms and public health authorities to improve distribution logistics and cold-chain management. Government epidemiological data show rising zoonotic infection reporting globally, supporting sustained preparedness budgets. These measurable policy-driven trends indicate a structurally supported market trajectory anchored in national health security priorities.
Tecovirimat Market Dynamics
Market Drivers
Government biodefense funding remains the principal driver of the tecovirimat market. The U.S. department of health and human services continues to maintain strategic national stockpiles of antivirals targeting smallpox under project bioshield funding mechanisms. Federal budget allocations for medical countermeasures have consistently exceeded several billion dollars annually, supporting procurement contracts for orthopoxvirus therapies. Additionally, the centers for disease control and prevention reported thousands of confirmed monkeypox cases during peak outbreak periods in 2022, accelerating emergency use authorizations and distribution programs.
Internationally, the European centre for disease prevention and control strengthened surveillance coordination across member states, increasing cross-border procurement frameworks. Rising global urbanization and increased international travel, reported by the world bank to have rebounded strongly post-pandemic, elevate transmission risk for zoonotic infections. Pediatric and geriatric population growth in developed economies also reinforces preparedness demand, as these groups show higher vulnerability to viral complications.
Market Restraints
Despite strong public health backing, the tecovirimat market faces structural restraints linked to limited commercial application and regulatory constraints. Smallpox remains eradicated globally according to the world health organization, significantly restricting routine clinical demand. As a result, procurement is primarily government-driven, limiting open-market commercialization. Furthermore, emergency use authorizations often require extensive pharmacovigilance reporting, adding compliance costs and administrative burdens.
Manufacturing scalability is another constraint. Antiviral production requires specialized containment facilities and regulatory oversight, increasing capital intensity. Budgetary reallocations during competing public health crises can also reduce procurement volumes, influencing tecovirimat market growth cycles. Additionally, distribution is largely centralized through hospital pharmacies and national stockpiles, restricting retail pharmacy penetration. Intellectual property limitations and dependency on government contracts create revenue concentration risks for manufacturers.
Government audit reviews have periodically emphasized cost-efficiency evaluations in stockpiling programs, potentially tightening procurement volumes. These regulatory, financial, and structural limitations collectively temper broader commercialization potential despite ongoing preparedness efforts.
Market Opportunities
Opportunities in the tecovirimat market are closely tied to expanding global outbreak preparedness frameworks and diversified formulation development. The world health organization has emphasized strengthening antiviral access in low- and middle-income countries, opening potential procurement pathways beyond traditional Western markets. Increasing zoonotic disease incidence reported by the United Nations environment programme highlights the need for scalable antiviral reserves.
Product innovation offers additional growth avenues. Development of pediatric oral suspensions and temperature-stable injectables can broaden therapeutic reach in resource-limited regions. Government-funded research grants under agencies such as barda and the European commission’s health emergency preparedness and response authority provide financial support for advanced manufacturing expansion. Integration of digital supply chain monitoring tools enhances transparency and reduces wastage, improving cost-effectiveness for national stockpiles.
Strategic partnerships between biotechnology firms and global health organizations may enable pooled procurement mechanisms. Collectively, rising global health security funding and formulation diversification create measurable long-term revenue visibility within institutional purchasing channels.
Market Challenges
The tecovirimat market encounters operational and strategic challenges centered on demand unpredictability and dependency on outbreak cycles. Infection incidence fluctuates significantly year to year, complicating production planning and inventory management. The world health organization has noted periodic containment success following vaccination and awareness campaigns, which may reduce short-term antiviral deployment.
Another challenge is maintaining product stability over long storage periods within national reserves. Antiviral shelf-life management requires ongoing replacement contracts, creating logistical complexity. Additionally, clinical data limitations in pediatric populations can slow regulatory label expansion. Market entry barriers remain high due to strict biocontainment manufacturing requirements and government qualification standards.
Competitive pressure from alternative orthopoxvirus therapies under development may also influence tecovirimat market share dynamics over time. These factors collectively require careful contract structuring, risk-sharing procurement models, and continuous regulatory engagement to sustain market viability.
Impact of War, Trade Protectionism, and Artificial Intelligence
The tecovirimat market has experienced indirect impacts from geopolitical tensions and supply chain disruptions. Trade protectionism has influenced pharmaceutical raw material sourcing, particularly where active pharmaceutical ingredients depend on cross-border manufacturing. The world bank reported pharmaceutical trade flow volatility during recent geopolitical conflicts, affecting delivery timelines for emergency medical supplies. Such disruptions may temporarily influence tecovirimat market size within national stockpiling programs.
Artificial intelligence, however, is emerging as a supportive force. Ai-driven epidemiological modelling enhances outbreak prediction accuracy, enabling earlier antiviral procurement decisions. Government-backed ai health surveillance initiatives in the United States and Europe are strengthening real-time data analysis capabilities. Over the coming years, ai-assisted demand forecasting and optimized inventory turnover are expected to enhance procurement efficiency and long-term stockpile sustainability.
Tecovirimat Market Segmentation Insights
Tecovirimat Market Analysis, By Product Form
By product form, the market is categorized into transdermal patch, injectable, oral, and topical cream.
- The oral segment represents the largest category within the market size due to its ease of administration, longer shelf stability, and suitability for rapid government-led deployment programs. Oral capsules are preferred in outbreak containment because they simplify logistics, reduce hospitalization requirements, and enable decentralized distribution through hospital pharmacies and controlled patient channels. Regulatory approvals and emergency access protocols have primarily focused on oral formulations, reinforcing their institutional dominance and strengthening tecovirimat market share. Governments prioritize oral stockpiling because capsules are easier to transport, store, and distribute at scale without complex cold-chain infrastructure.
- The injectable segment is projected to be the fastest-growing category in the market growth trajectory. Injectable formulations are increasingly prioritized for hospitalized, immunocompromised, and severe infection cases requiring controlled dosing and immediate antiviral action. Clinical guidelines in multiple jurisdictions emphasize intravenous options for high-risk patients, including pediatric and geriatric populations who may not tolerate oral administration effectively. Hospitals prefer injectable antivirals for critical care scenarios because dosing can be closely monitored, ensuring optimal therapeutic outcomes. As surveillance systems improve and outbreak response frameworks become more structured, hospitals are expanding preparedness inventories beyond oral stockpiles to include injectable reserves.
Tecovirimat Market Analysis, By Application
By application, the market is categorized into cowpox treatment, other orthopoxvirus infections, monkeypox treatment, and smallpox treatment.
- The smallpox treatment segment remains the largest within the tecovirimat market size due to its foundational role in national biodefense strategies. Although smallpox has been eradicated globally, governments continue to maintain antiviral stockpiles as a precaution against bioterrorism risks. Public health authorities classify smallpox preparedness as a strategic national security priority, resulting in long-term procurement contracts and structured replacement cycles. The eradication status paradoxically strengthens stockpiling policies, as population immunity has declined significantly since routine vaccination ceased decades ago. Regulatory frameworks and federal funding programs continue to allocate resources specifically for orthopoxvirus countermeasures targeting smallpox, reinforcing its central role in procurement decisions.
- The monkeypox treatment segment is the fastest-growing application area within the market growth structure. The 2022–2024 outbreak cycles triggered emergency declarations in several regions, prompting rapid antiviral deployment and expanded clinical access protocols. Unlike smallpox, monkeypox infections generate active and measurable treatment demand during outbreak periods, leading to increased utilization beyond stockpiling. Surveillance reports from public health authorities documented thousands of confirmed cases during peak transmission phases, accelerating procurement volumes. Expanded testing, improved case detection, and international coordination have increased clinical visibility, further driving antiviral adoption.
Tecovirimat Market Analysis, By Age Group
By age group, the market is categorized into adult, geriatric, and pediatric.
- The adult segment holds the largest position in the market share distribution due to higher reported infection rates within working-age populations during recent outbreak cycles. Surveillance data from public health authorities indicate that a majority of documented orthopoxvirus cases have occurred in adults, particularly in urban and high-mobility demographics. Clinical trial data and emergency use authorizations initially prioritized adult dosing protocols, reinforcing treatment accessibility in this group. Governments structure antiviral deployment frameworks primarily around adult case management strategies, further consolidating demand. Additionally, adult populations demonstrate higher cross-border travel and occupational exposure patterns, increasing infection vulnerability.
- The pediatric segment is the fastest-growing within the market growth outlook. Regulatory agencies are increasingly prioritizing dosage studies and safety evaluations tailored to younger populations. Although pediatric infection incidence is lower than adult rates, health authorities emphasize equitable access and vulnerability protection for children during outbreak containment efforts. Expansion of weight-based dosing protocols and formulation adjustments, including liquid suspensions, are broadening clinical usability. Governments are integrating pediatric treatment planning into national preparedness strategies to address population-wide immunity gaps. Additionally, improved diagnostic awareness in family healthcare settings is increasing early case identification among younger patients.
Tecovirimat Market Analysis, By Distribution Channel
By distribution channel, the market is categorized into direct patient channels, hospital pharmacies, online pharmacies, and retail pharmacies.
- The hospital pharmacies segment dominates the market size due to centralized outbreak management and government-controlled distribution systems. Antiviral deployment is typically coordinated through hospital networks, which serve as primary treatment centers during orthopoxvirus outbreaks. Institutional stockpiles are stored and dispensed under strict regulatory supervision, limiting broader retail circulation. Hospitals manage severe and high-risk cases, ensuring that injectable and controlled oral therapies remain under clinical oversight. Emergency use authorizations often mandate structured reporting, further reinforcing hospital-based dispensing channels. Because the majority of procurement contracts are government-funded and tied to institutional healthcare systems, hospital pharmacies maintain the largest distribution share.
- Online pharmacies represent the fastest-growing distribution channel within the tecovirimat market growth landscape. The expansion of telemedicine and digital prescription platforms has increased the feasibility of controlled remote dispensing, particularly for mild outpatient cases managed under public health supervision. Governments are exploring digital distribution pathways to improve accessibility while maintaining pharmacovigilance oversight. Secure digital verification systems and prescription authentication technologies are enhancing regulatory confidence in online dispensing models. Although still smaller than hospital-based distribution, online channels are expanding rapidly due to convenience, digital health integration, and broader telehealth adoption trends.
Tecovirimat Market Analysis, By End User
By end user, the market is categorized into clinics, home care settings, hospitals, and research institutes.
- Hospitals represent the largest end-user segment within the market framework due to their central role in outbreak response and severe case management. National preparedness plans allocate antiviral reserves primarily to hospital systems, where treatment protocols can be supervised by infectious disease specialists. Hospitals also serve as focal points for reporting, pharmacovigilance monitoring, and regulatory compliance. The presence of isolation units and advanced diagnostic capabilities further strengthens their dominance. Because government procurement channels prioritize institutional healthcare infrastructure, hospitals remain the principal recipients of antiviral allocations, ensuring sustained segment leadership.
- Research institutes are the fastest-growing end-user category within the tecovirimat market growth projection. Increasing public funding for antiviral research, outbreak modeling, and therapeutic optimization is expanding institutional demand. Research institutes conduct clinical trials, formulation improvements, and pharmacokinetic evaluations to enhance preparedness frameworks. Collaboration between biotechnology companies and academic institutions is intensifying, supported by government grants targeting emerging infectious diseases. As global emphasis on proactive outbreak prevention grows, research-driven procurement volumes are rising faster relative to other end-user groups, positioning research institutes as the most rapidly expanding segment in the overall tecovirimat market ecosystem.
Tecovirimat Market Regional Insights
North America
The North America tecovirimat market is primarily driven by structured biodefense funding, advanced surveillance infrastructure, and centralized antiviral stockpiling programs. The U.S. tecovirimat market represents the core demand center due to sustained federal procurement under Project BioShield and the strategic national stockpile framework. The U.S. department of health and human services annually allocates billions of dollars toward medical countermeasures preparedness, including orthopoxvirus antivirals. During the 2022 monkeypox outbreak cycle, the centers for disease control and prevention reported more than 30,000 confirmed cases in the United States, prompting emergency distribution protocols and reinforcing tecovirimat market demand.
Canada complements regional preparedness through the public health agency of Canada, which strengthened zoonotic disease surveillance following the public health emergency declarations. North America maintains one of the most advanced disease reporting systems globally, supported by digital epidemiological tracking and laboratory confirmation capacity. The region’s strong regulatory environment enables rapid emergency use authorizations and procurement renewals.
Additionally, federal audit programs mandate periodic antiviral stockpile replacement based on shelf-life expiration, creating recurring procurement cycles. These structured funding mechanisms and measurable outbreak response investments collectively reinforce long-term institutional stability in the North America tecovirimat market.
Europe
The Europe tecovirimat market is expanding through coordinated public health preparedness strategies and cross-border procurement mechanisms. The European centre for disease prevention and control strengthened orthopoxvirus monitoring following the 2022 outbreak, with more than 25,000 confirmed cases reported across the European region during peak transmission periods. Germany, the UK, and France increased antiviral preparedness budgets through national health ministries, integrating orthopoxvirus countermeasures into broader emergency frameworks.
Germany’s federal ministry of health reinforced laboratory capacity and antiviral reserve policies to address immunity gaps created by the cessation of routine smallpox vaccination decades ago. The UK health security agency enhanced diagnostic testing and antiviral deployment pathways under emergency public health protocols. France similarly expanded infectious disease monitoring networks, supported by national hospital preparedness funding. Eurostat data indicate that public health expenditure across the European Union increased steadily post-pandemic, reflecting structural reinforcement of infectious disease preparedness systems.
Regulatory coordination through the European medicines agency has facilitated expanded access programs and harmonized clinical guidance. Cross-border cooperation agreements allow centralized procurement and rapid allocation across member states. These measurable institutional responses, combined with strengthened surveillance frameworks, are driving sustained market growth throughout Europe.
Asia Pacific
The Asia Pacific tecovirimat market is strengthening as regional governments enhance zoonotic disease preparedness and cross-border surveillance capacity. China, India, Japan, and South Korea have expanded infectious disease monitoring budgets following global outbreak cycles. According to the world bank, Asia Pacific accounts for more than half of global urban population growth, increasing cross-border mobility and potential transmission exposure.
The Japan tecovirimat market is supported by advanced pharmaceutical regulation and high laboratory diagnostic standards. Japan’s ministry of health, labour and welfare continues to invest in antiviral research programs and national stockpiling policies aligned with global preparedness recommendations. China has expanded its public health surveillance systems, including real-time infectious disease reporting platforms covering hundreds of millions of residents. India strengthened outbreak monitoring infrastructure following public health emergency coordination efforts, increasing institutional readiness in major metropolitan centers. South Korea has invested heavily in digital contact tracing technologies and genomic sequencing capacity to monitor emerging pathogens.
Regional health ministries increasingly align with world health organization preparedness guidance, integrating orthopoxvirus response planning into broader zoonotic disease frameworks. These measurable investments in laboratory capacity, epidemiological surveillance, and digital monitoring systems are reinforcing long-term market demand across Asia Pacific.
Latin America
The Latin America tecovirimat market is gradually expanding as governments modernize infectious disease surveillance and hospital preparedness systems. Brazil, Argentina, and Chile are strengthening public health infrastructure in response to global zoonotic disease risks. During the 2022 outbreak cycle, Brazil reported several thousand confirmed orthopoxvirus cases, prompting enhanced antiviral response planning and reinforcing tecovirimat market demand within public hospitals.
Argentina’s ministry of health implemented improved epidemiological tracking protocols to increase early case detection and containment efficiency. Chile strengthened laboratory diagnostics capacity and cross-border reporting coordination, supported by regional public health cooperation agreements. According to the economic commission for Latin America and the Caribbean, healthcare expenditure across the region has shown steady incremental growth in recent years, reflecting improved institutional investment in disease preparedness.
Although procurement volumes remain more centralized and smaller relative to North America and Europe, the region is prioritizing antiviral readiness under broader pandemic preparedness strategies. Infrastructure modernization, digital reporting improvements, and expanded hospital networks are contributing to measurable structural reinforcement. These developments are supporting steady market growth across Latin America, particularly within public-sector procurement channels.
Middle East & Africa
The Middle East & Africa tecovirimat market is shaped by infrastructure development, expanding laboratory capacity, and increased infectious disease preparedness funding. Saudi Arabia and South Africa are key regional contributors. Saudi Arabia has strengthened national disease surveillance systems under its public health modernization initiatives, integrating advanced laboratory diagnostics and emergency response protocols. South Africa expanded genomic sequencing capacity through national health laboratory services, improving detection of emerging pathogens.
According to the world bank, several Sub-Saharan African countries have increased public health spending since 2020 to strengthen epidemic response systems. Urbanization across the region continues to accelerate, increasing exposure to zoonotic transmission risks. The world health organization has emphasized strengthening antiviral access frameworks in lower- and middle-income countries, prompting policy-level planning for orthopoxvirus preparedness.
Desert climate conditions and high population mobility in parts of the Middle East require rapid-response medical supply systems, reinforcing institutional antiviral reserves. Although logistical constraints and funding variability remain challenges, ongoing investments in hospital infrastructure, laboratory modernization, and surveillance digitization are creating measurable support for long-term market demand across the Middle East & Africa region.
Tecovirimat Market Competitive Overview
The tecovirimat market is highly concentrated, characterized by a limited number of biotechnology firms operating within strict regulatory and biodefense procurement frameworks. Established players dominate due to exclusive regulatory approvals, validated manufacturing capabilities, and long-term government supply agreements. Entry barriers remain high because antiviral production requires specialized containment facilities, pharmacovigilance compliance, and qualification under national stockpile standards. The competitive landscape consists primarily of established biodefense contractors, a smaller group of emerging antiviral developers, and niche research-focused entities.
Leading companies focus on securing multi-year government contracts, expanding formulation pipelines, and strengthening regulatory alignment across jurisdictions. Collaboration with public health agencies and research institutions is a key competitive strategy, ensuring readiness for outbreak-driven demand cycles. Strategic partnerships, manufacturing scalability, and compliance with emergency preparedness mandates remain the primary determinants of sustained competitive positioning within the global tecovirimat market.
Leading Market Players in the Tecovirimat Market
- Bavarian Nordic A/S: Bavarian Nordic A/S is a biotechnology company with a strong focus on infectious disease preparedness, including vaccines and antiviral countermeasures targeting orthopoxviruses. The company plays an important role in the broader tecovirimat market ecosystem through its strategic alignment with national biodefense initiatives and global immunization programs. Bavarian Nordic has developed expertise in large-scale vaccine production and regulatory compliance, enabling it to collaborate closely with government agencies and international health organizations. Its operational model emphasizes long-term preparedness contracts, manufacturing reliability, and integration of antiviral and vaccine response frameworks. The company’s infrastructure supports high-quality production standards required under emergency procurement agreements.
- Chimerix Inc.: Chimerix Inc. is a biopharmaceutical company specializing in the development and commercialization of antiviral therapies targeting serious viral infections. The company has been directly associated with the advancement and regulatory engagement of tecovirimat within multiple jurisdictions. Chimerix focuses on aligning its product development pipeline with government-funded biodefense priorities, ensuring compliance with stringent regulatory frameworks governing emergency medical countermeasures. Its strategy centers on clinical data generation, lifecycle management, and maintaining scalable manufacturing partnerships capable of supporting national stockpiling requirements. Chimerix works closely with public health authorities to facilitate emergency access programs and pharmacovigilance reporting systems.
- SIGA Technologies Inc.: SIGA Technologies Inc. is a biotechnology company focused on developing antiviral countermeasures for orthopoxvirus infections, with tecovirimat representing its flagship therapeutic asset. The company has established itself as a primary supplier under government biodefense procurement contracts, emphasizing readiness, compliance, and manufacturing reliability. SIGA Technologies maintains specialized production infrastructure that meets high-level biosafety and regulatory standards required for antiviral countermeasure manufacturing. Its business model prioritizes long-term supply agreements with national health authorities and strategic stockpile programs. The company also engages in ongoing pharmacovigilance monitoring and post-authorization regulatory commitments to ensure sustained compliance.
Top Strategies Followed by Players
- Government Contract Integration: A central strategy followed by leading companies in the tecovirimat market is the integration of long-term government procurement contracts into their core revenue structure. Because antiviral demand is largely institutional and outbreak-driven, firms prioritize securing multi-year agreements under national stockpiling and biodefense programs. This approach provides revenue visibility and mitigates demand volatility associated with fluctuating outbreak cycles. Companies invest heavily in regulatory compliance, quality assurance systems, and pharmacovigilance reporting to meet strict contractual obligations. Maintaining readiness for emergency deployment is a critical component of these agreements, requiring inventory management and manufacturing scalability. Firms also coordinate closely with health agencies to align production timelines with stockpile replenishment schedules.
- Formulation Diversification and Lifecycle Expansion: Another important strategy involves diversifying formulations and expanding product lifecycle management to enhance clinical applicability. Companies invest in developing injectable variants, pediatric-friendly dosing formats, and temperature-stable formulations to address evolving treatment needs. This diversification enables broader inclusion in hospital protocols and improves accessibility across vulnerable population groups. Lifecycle management efforts also include extended shelf-life optimization, packaging improvements, and stability testing to support national reserve requirements. Research partnerships with academic institutions and clinical networks help validate expanded use cases and improve safety data across age groups. By strengthening therapeutic flexibility, firms enhance their value proposition within procurement evaluations.
- Strategic Collaboration and Research Alignment: Leading players emphasize strategic collaboration with public health authorities, research institutes, and international health organizations to reinforce long-term preparedness positioning. Partnerships facilitate shared data exchange, outbreak modeling integration, and coordinated response planning. Companies often participate in government-funded research programs aimed at improving antiviral performance, optimizing dosing strategies, and exploring expanded orthopoxvirus indications. Collaborative engagement also enhances regulatory alignment across jurisdictions, reducing approval delays during emergency situations. Joint research initiatives contribute to strengthening pharmacovigilance systems and improving clinical evidence frameworks. Additionally, collaboration supports supply chain resilience by coordinating production capacity planning with national preparedness agencies.
List of Companies Profiled in the Report are:
Tecovirimat Market Recent Developments
Jan 2025: SIGA Tecovirimat (TEPOXX) received regulatory approval in Japan from the Pharmaceuticals and Medical Devices Agency (PMDA) for the treatment of orthopoxviruses including smallpox, monkeypox (mpox) and cowpox in adults and pediatric patients ≥13 kg.
July 2025: The European Medicines Agency (EMA) initiated a review of Tecovirimat-SIGA’s effectiveness in treating mpox following emerging clinical data showing limited efficacy in recent mpox studies; this review could influence future marketing authorizations across EU member states.
July 2025: NanoViricides, Inc. received ethics approval in the Democratic Republic of Congo to proceed with a Phase II clinical trial of its broad-spectrum antiviral candidate NV-387 targeting mpox, positioning it as a potential competitor antiviral to existing tecovirimat therapies in orthopoxvirus treatment.
By Product Form By Application By Age Group By Distribution Channel By End User
Global Tecovirimat Market Report Scope and Key Segmentation
Attributes
Report Details
2025 Market Size USD 122.69 Million 2026 Market Size USD 145.23 Million 2034 Revenue Forecast USD 559.74 Million Growth Rate 18.37% from 2026-2034 Study Period 2026-2034 Units Used USD Billion, Tons Key Segments Geographical Coverage Companies Profiled
*List of companies to be profiled in the report can be customized.
List of Segments Covered
This section of the market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Product Form By Application By Age Group By Distribution Channel By End User
Frequently Asked Questions (FAQs) about this Report
How big is the Global Tecovirimat market?
What is the Global Tecovirimat market growth?
Which country holds the highest share in the Global Tecovirimat market?
How is the Global Tecovirimat market segmented in the report?
Who are the key players in the Global Tecovirimat market?
What are the factors driving the tecovirimat market?
Which segment accounted for the largest tecovirimat market share?
Author

Chitra Patil
Senior Market Research Analyst – Healthcare & Life Sciences
Chitra Patil is a market research professional with over 7+ years of experience in the Healthcare & Life Sciences industry. She specializes in delivering comprehensive market intelligence across diverse healthcare segments, including Healthcare Services, Healthcare IT, Medical Devices, Pharmaceuticals, Biotechnology, and Animal Nutrition and Wellness. Her work focuses on identifying emerging trends, evaluating market dynamics, and providing actionable insights that support strategic business decisions in regulated healthcare environments. Her professional responsibilities include market sizing, growth forecasting, demand analysis, competitive intelligence, and evaluation of technological innovations in healthcare delivery systems and life sciences products. She has successfully contributed to the development of multiple healthcare-focused research studies that support manufacturers, healthcare providers, technology firms, and pharmaceutical stakeholders.
Read more about Chitra PatilCOMPANY
CONTACT
UG-203, Gera Imperium Rise, Wipro Circle Metro Station, Hinjawadi, Pune - 411057
- sales@valuemarketresearch.com
- +1-888-294-1147
BUSINESS HOURS
Monday to Friday : 9 A.M IST to 6 P.M IST
Saturday-Sunday : Closed
Email Support : 24 x 7
© , All Rights Reserved, Value Market Research